Anavex Life Sciences (AVXL) closed the last trading session at $6.29, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $39.67 indicates a 530.7% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $0.58. While the lowest estimate of $39 indicates a 520% increase from the current price level, the most optimistic analys ...

Core Insights - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment based on recent earnings estimate increases [1] Company Summaries - **Inhibikase Therapeutics, Inc. (IKT)**: The pharmaceutical company has seen a 16% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - **Eldorado Gold Corporation (EGO)**: This mining and mineral exploration company has experienced an 11.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - **MongoDB, Inc. (MDB)**: The database platform company has reported a 23.9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - **PagerDuty, Inc. (PD)**: This digital operations platform company has seen a 16.1% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - **Anavex Life Sciences Corp. (AVXL)**: The biopharmaceutical company has experienced a 14.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1]

Investors might want to bet on Anavex Life Sciences (AVXL) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ye ...

Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia validated clinical outcomes PANSS and EEG/ERP biomarkers Trial to study positive, negative, and cognitive domains of Schizophrenia based on ANAVEX®3-71's ability to synergistically activate both SIGMAR1 and M1 muscarinic receptors NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing di ...

BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ:AVXL) for potential securities law violations. Investors who have lost money in their Anavex Life Sciences Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/avxl. What is this all about? On January 2, Anavex announced results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX ...

One stock that might be an intriguing choice for investors right now is Anavex Life Sciences Corp. (AVXL) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably ta ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2023 Earnings Call Transcript November 27, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Trading Tom Bishop - Bishop Research Operator Good morning, and welcome to the Anavex Life Sciences Fiscal 2023 Fourth Quarter Conference Call. My name is Clint Tomlinson and I will be your host for today's call. At this time all pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to________________ Commission file number: 001-37606 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 98-06084 ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q3 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Trading Operator Good morning and welcome to the Anavex Life Sciences’ Fiscal 2023 Third Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today’s call. At this time, all participants are in a listen-only ...

PART I – FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS) Anavex Life Sciences Corp. reported a **$37.4 million net loss** for the nine months ended June 30, 2023, with cash increasing to **$154.8 million** from financing activities Condensed Consolidated Balance Sheet Highlights (Unaudited) | Account | June 30, 2023 ($) | September 30, 2022 ($) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $154,817,164 | $149,157,861 | | Total Assets | $157,809,863 | $152,704,603 | | **Liabilities & Equity** | | | | Total Liabilities | $11,055,267 | $10,213,561 | | Total Stockholders' Equity | $146,754,596 | $142,491,042 | | Total Liabilities and Stockholders' Equity | $157,809,863 | $152,704,603 | Condensed Consolidated Statements of Operations Highlights (Unaudited) | Metric | Nine Months Ended June 30, 2023 ($) | Nine Months Ended June 30, 2022 ($) | | :--- | :--- | :--- | | Research and development | $33,656,364 | $26,534,297 | | General and administrative | $9,447,447 | $9,167,560 | | Total operating expenses | $43,103,811 | $35,701,857 | | Operating loss | $(43,103,811) | $(35,701,857) | | Net loss | $(37,358,973) | $(33,687,519) | | Net Loss per share (Basic and diluted) | $(0.47) | $(0.44) | Condensed Consolidated Statements of Cash Flows Highlights (Unaudited) | Cash Flow Activity | Nine Months Ended June 30, 2023 ($) | Nine Months Ended June 30, 2022 ($) | | :--- | :--- | :--- | | Net cash used in operating activities | $(21,935,371) | $(20,193,929) | | Net cash provided by financing activities | $27,594,674 | $21,285,536 | | Increase in cash and cash equivalents | $5,659,303 | $1,091,607 | - The company is a clinical-stage biopharmaceutical firm focused on developing therapeutics for central nervous system (CNS) diseases, with its lead compound, ANAVEX2-73, in development for Alzheimer's, Parkinson's, and Rett syndrome[23](index=23&type=chunk) - During the nine months ended June 30, 2023, the company issued **3,138,348 shares** of common stock, raising aggregate proceeds of **$26,687,017** under the 2023 Purchase Agreement with Lincoln Park[56](index=56&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=18&type=section&id=ITEM%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS.) The MD&A highlights the company's clinical-stage status, increased operating expenses to **$43.1 million**, a widened net loss of **$37.4 million**, and a strong liquidity position with **$154.8 million** in cash [Business Overview and Clinical Pipeline](index=19&type=section&id=Business%20Overview%20and%20Clinical%20Pipeline) Anavex is a clinical-stage biopharmaceutical company developing therapeutics for CNS diseases, with lead compound ANAVEX2-73 showing promise in multiple trials - Anavex is a clinical-stage biopharmaceutical company developing therapeutics for CNS diseases like Alzheimer's, Parkinson's, and Rett syndrome, using a precision medicine approach with genomic biomarkers[83](index=83&type=chunk) - The lead product, ANAVEX2-73, has completed a Phase 2b/3 trial for Alzheimer's disease, meeting co-primary and key secondary endpoints by slowing cognitive and functional decline[89](index=89&type=chunk)[90](index=90&type=chunk) - In Rett Syndrome, the ANAVEX2-73 program includes the completed AVATAR Phase 3 trial, which met all primary and secondary endpoints, and the ongoing EXCELLENCE Phase 2/3 pediatric trial, with topline results expected in the second half of 2023[98](index=98&type=chunk)[99](index=99&type=chunk) - The ANAVEX2-73 Phase 2 trial in Parkinson's disease dementia showed statistically significant improvements in cognitive measures, and a 48-week open-label extension demonstrated longitudinal beneficial effects[101](index=101&type=chunk)[102](index=102&type=chunk)[105](index=105&type=chunk) - ANAVEX3-71, another pipeline candidate, has completed a Phase 1 trial for Frontotemporal Dementia (FTD) and is being advanced into a biomarker-driven program for dementia, schizophrenia, and Alzheimer's[107](index=107&type=chunk)[110](index=110&type=chunk) [Results of Operations](index=32&type=section&id=Results%20of%20Operations) Operating expenses increased to **$43.1 million** for the nine months ended June 30, 2023, primarily due to higher R&D costs, leading to a net loss of **$37.4 million** Comparison of Operating Expenses (in millions) | Expense Category | Three Months Ended June 30, 2023 ($M) | Three Months Ended June 30, 2022 ($M) | Nine Months Ended June 30, 2023 ($M) | Nine Months Ended June 30, 2022 ($M) | | :--- | :--- | :--- | :--- | :--- | | Research & Development | $10.3 | $9.3 | $33.7 | $26.5 | | General & Administrative | $3.2 | $3.2 | $9.4 | $9.2 | | **Total Operating Expenses** | **$13.5** | **$12.5** | **$43.1** | **$35.7** | - The increase in R&D expenses for the nine-month period was primarily due to higher personnel costs (**$1.8M**), stock-based compensation (**$1.1M**), manufacturing activities (**$2.9M**), new trial start-up costs (**$0.4M**), and expanded enrollment in the EXCELLENCE trial (**$1.6M**)[163](index=163&type=chunk) Net Loss Summary | Metric | Three Months Ended June 30, 2023 ($M) | Three Months Ended June 30, 2022 ($M) | Nine Months Ended June 30, 2023 ($M) | Nine Months Ended June 30, 2022 ($M) | | :--- | :--- | :--- | :--- | :--- | | Net Loss | $(11.3M) | $(12.4M) | $(37.4M) | $(33.7M) | | Loss Per Share | $(0.14) | $(0.16) | $(0.47) | $(0.44) | [Liquidity and Capital Resources](index=34&type=section&id=Liquidity%20and%20Capital%20Resources) The company's cash and cash equivalents increased to **$154.8 million**, supported by a **$150 million** purchase agreement with Lincoln Park Capital, ensuring sufficient funding Working Capital Summary | Account | June 30, 2023 ($) | September 30, 2022 ($) | | :--- | :--- | :--- | | Current Assets | $157,809,863 | $152,704,603 | | Current Liabilities | $11,055,267 | $10,213,561 | | **Working Capital** | **$146,754,596** | **$142,491,042** | - Cash and cash equivalents increased to **$154.8 million** at June 30, 2023, from **$149.2 million** at September 30, 2022, driven by **$27.6 million** in financing activities, partially offset by **$21.9 million** used in operations[167](index=167&type=chunk)[178](index=178&type=chunk) - On February 3, 2023, the company entered into a **$150 million** purchase agreement with Lincoln Park Capital Fund, LLC, with **$123.3 million** remaining available as of June 30, 2023[179](index=179&type=chunk)[184](index=184&type=chunk) - No shares were sold under the Controlled Equity Offering Sales Agreement during the nine months ended June 30, 2023, unlike the prior year period which raised **$21.0 million** in gross proceeds[187](index=187&type=chunk) [Quantitative and Qualitative Disclosures About Market Risks](index=37&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISKS.) The company reports no material changes in its market risk exposure since the Annual Report on Form 10-K for the fiscal year ended September 30, 2022 - There have been no material changes in the company's market risk exposure since its last annual report[192](index=192&type=chunk) [Controls and Procedures](index=37&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES) As of June 30, 2023, disclosure controls and procedures were deemed effective, with no material changes to internal control over financial reporting during the quarter - Management, including the CEO and principal financial officer, concluded that the company's disclosure controls and procedures were effective as of June 30, 2023[194](index=194&type=chunk) - No changes to internal control over financial reporting occurred during the quarter ended June 30, 2023, that have materially affected or are likely to materially affect internal controls[195](index=195&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=38&type=section&id=ITEM%201.%20LEGAL%20PROCEEDINGS) The company reports no material pending legal proceedings beyond routine litigation incidental to its business - The company is not aware of any material pending legal proceedings[197](index=197&type=chunk) [Risk Factors](index=38&type=section&id=ITEM%201A.%20RISK%20FACTORS) No material changes have occurred to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the fiscal year ended September 30, 2022 - No material changes have occurred to the risk factors disclosed in the company's 2022 Form 10-K[198](index=198&type=chunk) [Other Part II Items](index=38&type=section&id=Other%20Part%20II%20Items) The company reported no unregistered equity sales, defaults on senior securities, or mine safety disclosures for the period - The company reports no unregistered sales of equity securities, defaults upon senior securities, mine safety disclosures, or other information for the period[199](index=199&type=chunk) [Exhibits](index=39&type=section&id=ITEM%206.%20EXHIBIT) This section lists the exhibits filed with the Form 10-Q, including officer certifications and XBRL data files - The report includes a list of filed exhibits, such as officer certifications (**31.1, 31.2, 32.1**) and XBRL interactive data files (**101 series**)[201](index=201&type=chunk) [Signatures](index=40&type=section&id=SIGNATURES) - The report was duly signed and authorized on **August 8, 2023**, by Christopher Missling, PhD, Chief Executive Officer, and Sandra Boenisch, CPA, CGA, Principal Financial Officer[203](index=203&type=chunk)[204](index=204&type=chunk)